Juan Gumuzio

Archivel Farma SL provides research and development services to the pharmaceutical sector. It focuses on TB, more specifically, on the treatment of the latent TB infection diseases. The firm is association with the Germans Trias i Pujol Research Institut of Health Sciences and the Germans Trias i Pujol University Hospital has developed RUTI, the first therapeutic vaccine against TB. The company was founded in 2005 by José Martínez, Pere-Joan Cardona i Iglèsias, Jaume Amat i Reira and Isabel Amat i Riera and is headquartered in Badalona, Spain.

l'Associació Catalana d'Empreses de Biotecnologia is business association operating company. It is engaged in promoting health and life sciences activities for biotechnology organizations, business leaders, senior executives, entrepreneurs, investors and journalists. The company was founded in 2006 and is headquartered in Barcelona, Spain.

Kintsugi Therapeutics is a biomedical start-up based in Barcelona, Spain. The Spanish company focuses on developing innovative therapies for the treatment of liver conditions and other pathologies by targeting the regulation of endoplasmic reticulum stress. The company's lead candidate is a first-in-class endoplasmic reticulum stress inhibitor being developed for the treatment of non-alcoholic steatohepatitis (NASH). The company was founded by Carmen Herrero and Marc Cusachs, with Carmen Herrero serving as the CEO since incorporation.

Antalgenics SL is a Spanish biotechnological company that specializes in discovering and developing new bioactive molecules for biomedical and dermocosmetic applications. The company is based in Alicante, Spain. The company offers customized R & D services to design and develop projects according to the client's needs. The company's focus is on developing novel therapeutic leads, primarily for the treatment of psoriatic pruritus and psoriatic comorbidities. Antalgenics was founded in 2015, and the CEO is Philipp Tsolakis.

Prospera Biotech SL is a Spanish company that develops innovative solutions for sensitive skin caused by medical treatments and environmental agents. The company is based in Elche, Spain and was founded in 2019. The company's own formulations are free of aggressive agents and suitable for all types of skin. The company specializes in developing cosmetic formulations with innovative neurocosmetics for skin care in sensitive skin with a tendency to atopia, sensitive skins of people who have received chemotherapy and/or radiotherapy, sensitive skins in the intimate parts of the body, and excessive sweating. The CEO is Marta García.